Lupus Therapeutic Market, By Disease Type (Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus, Drug-Induced Lupus Erythematosus, and Neonatal Lupus), By Treatment Type (Non-Steroidal Anti-Inflammatory Drugs, Biologics, Antimalarial Drugs, Corticosteroids, and Others), By Route of Administration (Oral, Subcutaneous, Intravenous, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : May 2024

Code : CMI4958

Pages :167

Formats :

Excel and PDF

Industry : Pharmaceutical

Lupus Therapeutic Market Size and Trends

Global lupus therapeutic market is estimated to be valued at USD 3.25 Bn in 2024 and is expected to reach USD 5.91 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.9% from 2024 to 2031.

Lupus Therapeutic Market Key Factors

To learn more about this report, Request sample copy

The global lupus therapeutic market is expected to witness a positive growth trend over the forecast period. There is an increasing prevalence of lupus worldwide which is driving the demand for effective treatment options. Additionally, ongoing research and development activities for novel biologic therapies to treat lupus is expected to provide opportunities for market growth. Many pharmaceutical companies are making substantial investments in developing advanced monoclonal antibodies and other targeted drugs to address unmet needs in lupus treatment. However, high developmental costs of biologics combined with drug failure in late stages of clinical trials remains a challenge hampering the market growth to an extent.

Increasing Partnerships Among Key Market Players

Increasing adoption of inorganic growth strategies, such as partnerships, is expected to drive the market growth. For instance, in March 2023, U.S. FDA’s Center for Drug Evaluation and Research partnered with the Lupus Research Alliance (LRA) to launch the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), a first-of-its-kind public-private partnership focused on addressing challenges impacting lupus clinical trial success.

Lupus Therapeutic Market Concentration By Players

To learn more about this report, Request sample copy

Increasing Awareness Campaigns

Increasing awareness campaigns is expected to drive the market growth over the forecast period. For instance, in October 2022, Aurinia Pharmaceuticals Inc., a global biotechnology company, announced that it had launched a digital campaign aimed at boosting awareness around a form of lupus that causes kidney disease, and it is not shying away from the tough nature of the condition. The campaign helps to show the “highly relatable, although sometimes uncomfortable” situations involved in the routine monitoring of lupus nephritis and highlights the importance of protecting the kidneys.